Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).

Tanioka H, Miyamoto Y, Tsuji A, Asayama M, Shiraishi T, Yuki S, Kotaka M, Makiyama A, Shimokawa M, Shimose T, Masuda S, Yamaguchi T, Komatsu Y, Saeki H, Emi Y, Baba H, Oki E, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).

Oncology. 2018;94(5):289-296. doi: 10.1159/000486624. Epub 2018 Mar 7.

PMID:
29514163
2.

Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.

Fukuoka S, Shitara K, Noguchi M, Kawazoe A, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T.

Clin Colorectal Cancer. 2017 Jun;16(2):e39-e44. doi: 10.1016/j.clcc.2016.07.012. Epub 2016 Aug 18.

PMID:
27780748
3.

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group.

Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.

PMID:
23177514
4.

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.

Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N.

Lancet Oncol. 2016 Dec;17(12):1732-1742. doi: 10.1016/S1470-2045(16)30507-1. Epub 2016 Oct 14.

PMID:
27751846
5.

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.

Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW; CONCUR Investigators.

Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13.

PMID:
25981818
6.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators.

Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22.

7.

Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.

Crona DJ, Keisler MD, Walko CM.

Ann Pharmacother. 2013 Dec;47(12):1685-96. doi: 10.1177/1060028013509792. Epub 2013 Nov 1. Review.

PMID:
24259629
8.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators.

Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36.

PMID:
27932229
9.

[Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].

Tanaka A, Sadahiro S, Suzuki T, Okada K, Saito G.

Gan To Kagaku Ryoho. 2014 Oct;41(10):1231-6. Japanese.

PMID:
25335705
10.

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations.

Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, Hamada Y, Ohtsu A.

Invest New Drugs. 2015 Jun;33(3):740-50. doi: 10.1007/s10637-014-0154-x. Epub 2014 Sep 12.

11.

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.

Yoshino K, Manaka D, Kudo R, Kanai S, Mitsuoka E, Kanto S, Hamasu S, Konishi S, Nishitai R.

J Med Case Rep. 2017 Aug 18;11(1):227. doi: 10.1186/s13256-017-1366-4.

12.

Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.

Mitchell J, Khoukaz T, McNeal D, Brent L.

Clin J Oncol Nurs. 2014 Apr;18(2):E19-25. doi: 10.1188/14.CJON.E19-E25.

PMID:
24675266
13.

Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer.

Sugita K, Kawakami K, Yokokawa T, Mae Y, Toya W, Hagino A, Suzuki K, Suenaga M, Mizunuma N, Yamaguchi T, Hama T.

Anticancer Res. 2015 Jul;35(7):4059-62.

PMID:
26124355
14.

Regorafenib: A Review in Hepatocellular Carcinoma.

Heo YA, Syed YY.

Drugs. 2018 Jun;78(9):951-958. doi: 10.1007/s40265-018-0932-4. Review.

PMID:
29915898
15.

Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.

Røed Skårderud M, Polk A, Kjeldgaard Vistisen K, Larsen FO, Nielsen DL.

Cancer Treat Rev. 2018 Jan;62:61-73. doi: 10.1016/j.ctrv.2017.10.011. Epub 2017 Nov 10. Review.

PMID:
29175677
16.

Prevention and management of adverse events related to regorafenib.

De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, Ouwerkerk J, Raynard SS, Bazin A, Cremolini C.

Support Care Cancer. 2014 Mar;22(3):837-46. doi: 10.1007/s00520-013-2085-z. Epub 2013 Dec 14. Review.

17.

[Investigation of Administration Technique of Regorafenib in Our Center].

Matsuda C, Danno K, Miyazaki S, Fujitani K, Kubota M, Motoori M, Nakatsuka R, Nishimura M, Kitagawa A, Takagi M, Iwase K.

Gan To Kagaku Ryoho. 2017 Jan;44(1):47-51. Japanese.

PMID:
28174379
18.

Regorafenib in the treatment of metastatic colorectal cancer.

de la Fouchardière C.

Future Oncol. 2018 Sep;14(22):2239-2246. doi: 10.2217/fon-2017-0512. Epub 2018 Mar 23. Review.

PMID:
29569472
19.

Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer.

Cicero G, De Luca R, Dieli F.

Oncology. 2017;93(6):354-358. doi: 10.1159/000479112. Epub 2017 Sep 6.

PMID:
28873372
20.

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.

Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D.

J Clin Oncol. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20.

Supplemental Content

Support Center